HK Stock MarketDetailed Quotes

06606 NH HEALTH

Watchlist
  • 14.140
  • 0.0000.00%
Market Closed Mar 28 16:08 CST
6.47BMarket Cap53.36P/E (TTM)

About NH HEALTH Company

In 2015, Novartis Health was founded in Hangzhou, Zhejiang. It was the first biotech company in China focusing on early screening for high-incidence cancers at home. It was also the first in the industry to successfully list on the Hong Kong Stock Exchange, becoming the “first stock in early cancer screening in China”, stock code 6606.HK. With the mission of “changing the trajectory of life”, Nuohui Health adheres to the product concept that has a scientific basis, clinical verification, user needs, and market prospects, and invests heavily in self-developed multi-omics cancer screening technology innovation and product development. In response to colorectal cancer and stomach cancer, which are currently the most common digestive tract cancers in China, the company has separately listed and commercialized three pioneering star products in the industry: Chang Weiqing, Pu Pu, and Pu Yu. Chang Weiqing is the first cancer screening product approved by China's National Drug Administration. It is suitable for people aged 40 to 74 at high risk of colorectal cancer. Youtube is the first Helicobacter pylori consumer self-test product approved by China's National Drug Administration. The Pooh Tube is the first Fecal Blood (FIT) home self-tester approved in China. In addition, the company has three clinical products under development or about to be registered for screening for liver cancer (), cervical cancer (Gong zhengqing), and nasopharyngeal cancer (), as well as a number of other cancer screening pipeline products. The company holds global intellectual property rights for all of its listed and pipeline products. Based on the clinical market, Novartis Health has pioneered diversified business models in the early cancer screening industry, and has established extensive strategic cooperation with leading cross-border brands such as well-known medical examination chains, insurance companies, pharmacy chains, and various Internet medical platforms. The company's main products have entered nearly 1,000 hospitals across the country, forming a closed-loop early screening, diagnosis and treatment service combining outpatient and in-hospital physical examinations. Based on the domestic market, Novartis Health began overseas market exploration in 2022. In June, Novartis Health joined hands with US NASDAQ listed company Prenetics to launch Chang Weiqing in Hong Kong, China, and plans to gradually cover Macau and Taiwan in the future, thereby entering the Southeast Asian market. The company began construction of its first international R&D center at the Hong Kong Science and Technology Park at the same time, focusing on multi-omics R&D and product development including second-generation sequencing technology (NGS). Novartis Health, a publicly traded company, participated in the establishment of the NHH Venture Fund (NHH Venture Fund) in August 2021 to focus on investing in breakthrough innovative molecular diagnostic technology for major human diseases. Up to now, the company has reached investments or strategic partnerships with five of the world's leading cancer screening or testing biotech companies in the US, Germany, Switzerland and Singapore. Novartis Health has a 100,000 grade clean production workshop in Hangzhou that complies with ISO 13485 and ISO 9001 international certification standards, and has third party medical testing laboratories in Beijing, Hangzhou and Guangzhou. All three laboratories have obtained relevant international standard quality system certification and certification from the local Health and Health Commission and issued a license to practice.

Company Profile

Symbol06606
Company NameNH HEALTH
ISINKYG6485S1021
Listing Date02/18/2021
Issue Price26.66
Shares Offered76.60M share
Founded06/07/2018
RegistrationCayman Islands
ChairmanYeqing Zhu
SecretaryYu\mominghui Gao
Audit InstitutionDeloitte & Touche Tohmatsu Certified Public Accountants
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeConyers Trust Company (Cayman) Limited Cricket Square Hutchins Drive P.O. Box 2681 Grand Cayman KY1-1111 Cayman Islands
Head Office and Principal Place of Business5/F, Manulife Plaza, 348 Kwun Tong Road, Kowloon, Hong Kong
Fiscal Year Ends12-31
Employees1041
MarketHong Kong motherboard
Phone(0571)81107210
Fax(0571)86430935
EmailIR@nhbio.com.cn
Business New Horizon Health Ltd is a Chinese investment holding company mainly engaged in R&D, clinical development, test operation and commercialization of colorectal cancer, gastric cancer and cervical cancer screening products. The company sells Chang Weiqing, Pu Pu tube and other products to customers through its own network, contract sales organization (CSO), and online sales or electronic platforms operated by medical clinics. The company's pyloric tube (a self-test gastric cancer screening test based on feces) and Gong Zhengqing (a non-invasive home screening test for urinary cervical cancer) products are in the development stage.

Company Executives

  • Name
  • Position
  • Salary
  • Yiyou Chen
  • Chief Scientific Officer,Executive Director,Remuneration Committee Member
  • --
  • Yeqing Zhu
  • Chairman,Authorized Representative,Executive Director,CEO,Nomination Committee Chairman
  • --
  • Naxin Yao
  • Audit Committee Member,Non-Executive Director
  • --
  • Danke Yu
  • Audit Committee Chairman,Independent Non-Executive Director,Nomination Committee Member,Remuneration Committee Member
  • --
  • Hong Wu
  • Independent Non-Executive Director,Nomination Committee Member,Remuneration Committee Chairman
  • --
  • Guodong Li
  • Audit Committee Member,Independent Non-Executive Director
  • --
  • Yu Gao
  • Joint Company Secretary,CFO
  • --
  • Ning Lv
  • chief technology officer
  • --
  • Minghui Mo
  • Authorized Representative,Joint Company Secretary
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg